tinzaparin

Tinzaparin is a low molecular weight heparin (LMWH) anticoagulant used primarily for the treatment of acute symptomatic deep vein thrombosis (DVT), with or without pulmonary embolism, often in conjunction with warfarin. It is produced by enzymatic depolymerization of unfractionated heparin derived from porcine intestinal mucosa. Tinzaparin acts mainly by binding to antithrombin III, which accelerates the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This results in reduced thrombin generation and inhibition of fibrin clot formation. Tinzaparin also stimulates the release of tissue factor pathway inhibitor (TFPI), further contributing to its antithrombotic effect. It is administered subcutaneously or parenterally and has a higher affinity for anti-Xa activity compared to anti-IIa due to its molecular structure[2][4][6].

Brand names

Innohep

Other names

tinzaparin sodium